현대바이오

048410KOSDAQ기타 화학제품 제조업

45.9 / 100

Reference Date: 2026-04-13

Financial Score12.0 / 40

News Sentiment16.9 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hyundai BioScience, established in 2000 as a spin-off from Hyundai Electronics, specializes in bio-pharmaceuticals and cosmeceuticals, focusing on new drug development and functional cosmetics. After shutting down its IT business in 2018 and rebranding, the company expanded its R&D and production network through overseas joint ventures in Japan and the U.S., prioritizing the development of antiviral treatments and cancer drugs. However, it reported a revenue of 35 billion won, along with an operating loss of 18.2 billion won and a net loss of 22.1 billion won in its latest financial statements.

Number of Employees

67people

Average Salary

78.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 18.384.0Point

PBR

12.11Industry Average 1.370.0Point

8.8x industry avg (risky)

ROE

-29.47Industry Average 4.550.0Point

Well below industry avg

Debt Ratio

0.44Industry Average 8.138.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼8.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼1144.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -24.6% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 2Neutral 1Negative 0Average Sentiment Score 85

Positive
현대바이오사이언스, 뎅기치료제 임상 개시
현대바이오사이언스가 베트남 현지에서 뎅기 및 유사질환 치료제를 대상으로 한 임상시험 개시모임을 진행하고 범용항바이러스 치료제의 글로벌 임상을 본격적으로 시작한다.
Positive
현대바이오, ‘치료제 없는’ 뎅기 시장 정조준...글로벌 임상 개시
현대바이오사이언스가 세계적으로 승인된 치료제가 없는 뎅기열 시장을 공략하기 위해 베트남 현지에서 뎅기 및 유사질환 치료제에 대한 글로벌 임상시험 개시모임을 확정하고 4월 초 첫 투약을 목표로 하고 있다.
Neutral
코스닥 액티브 ETF가 점찍은 바이오…큐리언트·삼천당제약 '눈길'
코스닥 액티브 ETF가 지난 10일 상장되면서 바이오 투자 지형에 변화가 감지되고 있으며, 운용사별 포트폴리오 전략에 따라 편입 종목과 비중이 크게 갈리고 있다.

Detailed Momentum

52-week position6.0Point

52w upper range (60%)

Current 13,900Won52-week high 20,00052-week low 4,395

1-month return0.0Point

1m -16.72% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral[기재정정]사업보고서 (2025.12)2026-03-30
Neutral주식등의대량보유상황보고서(일반)2026-03-26
Neutral사업보고서 (2025.12)2026-03-18
Neutral감사보고서제출2026-03-17